How Many Diseases Are Colorectal Cancer?

por Greystoke, A., Mullamitha, S. A.
Publicado 2012

The interaction between prognostic and pharmacodynamic biomarkers

por Bouranis, L, Sperrin, M, Greystoke, A, Dive, C, Renehan, A G
Publicado 2013

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs

por Brookes, K, Cummings, J, Backen, A, Greystoke, A, Ward, T, Jayson, G C, Dive, C
Publicado 2010

Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours

por Harries, M, O'Donnell, A, Scurr, M, Reade, S, Cole, C, Judson, I, Greystoke, A, Twelves, C, Kaye, S
Publicado 2004

Biomarkers of apoptosis

por Ward, T H, Cummings, J, Dean, E, Greystoke, A, Hou, J M, Backen, A, Ranson, M, Dive, C
Publicado 2008

Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer

por Greystoke, A, Dean, E, Saunders, M P, Cummings, J, Hughes, A, Ranson, M, Dive, C, Renehan, A G
Publicado 2012

A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancer—the ChemoFit study prot...

por Chmelo, J., Phillips, A. W., Greystoke, A., Charman, S. J., Avery, L., Hallsworth, K., Welford, J., Sinclair, R. C. F.
Publicado 2020

A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity

por Gibb, A, Greystoke, A, Ranson, M, Linton, K, Neeson, S, Hampson, G, Illidge, T, Smith, E, Dive, C, Pettitt, A, Lister, A, Johnson, P, Radford, J
Publicado 2013

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders

por Rae, S., Plummer, E., Fitzgerald, L., Hogarth, L., Bridgewood, A., Brown-Schofield, L., Graham, J., Haigh, S., McAnulty, C., Drew, Y., Haris, N., Bashir, S., Plummer, R., Greystoke, A.
Publicado 2023

Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma

por Greystoke, A, O'Connor, J P B, Linton, K, Taylor, M B, Cummings, J, Ward, T, Maders, F, Hughes, A, Ranson, M, Illidge, T M, Radford, J, Dive, C
Publicado 2011

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

por Khan, O A, Gore, M, Lorigan, P, Stone, J, Greystoke, A, Burke, W, Carmichael, J, Watson, A J, McGown, G, Thorncroft, M, Margison, G P, Califano, R, Larkin, J, Wellman, S, Middleton, M R
Publicado 2011